Alegre, A. (A.)Mateo, G. (Gemma)Bladé, J. (Joan)García-Sanz, R. (Ramón)Hernandez, J.M. (J. M.)Mateos, M.V. (María Victoria)Arriba, F. (Felipe) deEsseltine, D.L. (D. L.)Hernandez, M.T. (Miguel Teodoro)Carrera, D. (D,)Garcia-Sanchez, P. (P.)Palomera, L. (Luis)Terol, M.J. (María José)Velde, H. (Helgi) van deLahuerta, J.J. (Juan José)Gutierrez, N.C. (Norma C.)Fuertes, M. (M.)Ribas, P. (Paz)Garcia-Laraña, J. (J.)Oriol, A. (Albert)Rubia, J. (Javier) de laProsper-Cardoso, F. (Felipe)Sureda-Balari, A. M. (Anna Maria)Bargay, J. (Joan)San-Miguel, J.F. (Jesús F.)2011-04-202011-04-202008Mateos, M.-V., Hernández. J. M., Hernández, M. T., Gutiérrez, N. C. et al Haematologica 2008; 93(4): 560-5650390-6078https://hdl.handle.net/10171/17831New treatment options offering enhanced activity in elderly, newly diagnosed patients with multiple myeloma are required. One strategy is to combine melphalan and prednisone with novel agents. We previously reported an 89% response rate, including 32% complete responses and 11% near complete responses, in our phase 1/2 study of bortezomib plus melphalan and prednisone (VMP) in 60 newly diagnosed multiple myeloma patients with a median age of 75 years. Here, we report updated time-to-events data and the impact of poor prognosis factors on outcome.enginfo:eu-repo/semantics/openAccessMaterias Investigacion::Ciencias de la Salud::OncologíaÁrea de Terapia Celularinfo:eu-repo/semantics/article